Ventria Bioscience Acquires Meristem Therapeutics' Recombinant Lactoferrin Intellectual Property

Published: Dec 03, 2012

FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience announces the completion of an agreement under which Ventria Bioscience will wholly acquire portions of the intellectual property portfolio relating to Recombinant Lactoferrin developed by the French biotechnology company, Meristem Therapeutics. The agreement transfers to Ventria Bioscience exclusive royalty-free ownership rights for the specific patents in the United States, France, and Canada, including those related to recombinant human lactoferrin, in exchange for a one-time payment. β€œThe patents acquired today cover important components of our product pipeline,” said Scott Deeter, president and CEO of Ventria Bioscience. β€œThe decision to purchase this intellectual property is significant because it removes the encumbrance of ongoing royalty and milestone payments, thereby enhancing the future economics of our products that use recombinant human lactoferrin.”

Back to news